News

Par acquires three generics from Teva

BY Allison Cerra

WOODCLIFF LAKE, N.J. — Par Pharmaceutical Cos. has acquired the rights to three generic drugs from another company.

Par said it has acquired from Teva Pharmaceutical Industries the abbreviated new drug applications for fentanyl citrate lozenges and cyclobenzaprine ER capsules (generic versions of Actiq and Amrix, respectively), as well as the U.S. rights to market modafinil tablets, the generic version of Provigil. The acquired rights were in connection to Teva’s acquisition of drug maker Cephalon, which was completed Friday.

Par currently is shipping to the trade all strengths of fentanyl citrate lozenges that were previously available from Teva. Cyclobenzaprine ER capsules and modafinil tablets were not previously marketed by Teva and are not yet available, Par said.


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Teva completes Cephalon acquisition

BY Allison Cerra

JERUSALEM — Teva Pharmaceutical Industries has completed its acquisition of another drug maker, following clearance from the Federal Trade Commission.

Teva said its acquisition of Frazier, Pa.-based Cephalon, valued at $6.8 billion, will help the company build out its branded and specialty pharmaceuticals business. The combined company is expected to generate about $20 billion in revenues (on a pro-forma basis) for the 12 months ended in June.

In relation to the deal, Teva sold three generic drugs to Par Pharmaceutical Cos.


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Prasco to bring Aspen brand to U.S. market

BY Allison Cerra

CINCINNATI — Prasco Labs announced it will serve as the exclusive U.S. distributor and pharmaceutical services provider for a line of branded prescription drugs.

Prasco said that it will distribute products under the Aspen Global brand, the generic drug maker said. Aspen currently serves Africa, Latin America, Europe, Australia and Asia markets.

“Our relationship with Aspen is a natural extension of our proprietary lifecycle management system,” Prasco CEO E. Thomas Arington said. “We have a history of success in marketing branded products as Prasco authorized generics. These established relationships provide a platform for extending our services to brand markets. By utilizing our expertise, Prasco will provide partner specific distribution and product support services through all distribution channels.”


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?